EU allocates EUR 3.6 million in funding for development of CombiGene’s cuttingedge gene therapy

May 15, 2018

Horizon 2020, the EU framework programme for research and development, will invest 3.6 million euros in CombiGene’s ongoing development and commercialization of the company’s gene therapy project focussing on difficult-to-treat epilepsy.
Read more>>